Patents as we have known in the past now are starting to look somewhat simplistic when compared to today's cases relative to "Intelligent Property", which much of course involves software, and this case has been pretty heated and complicated from the day it began, as the products are stents and catheters being debated. BD
NATICK, Mass., Aug. 29 /-/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. District Court of Marshall, Texas found two patents of Medtronic, Inc. (NYSE: MDT) unenforceable for inequitable conduct during the prosecution of the patents before the United States Patent and Trademark Office. A jury had previously found that certain Boston Scientific balloon catheters and stent delivery systems infringed three Medtronic patents and that the patents were valid. The jury awarded damages of $250 million. As a result of today's decision, the damages are reduced to approximately $19 million. Following a prior decision by the Court, Medtronic and Boston Scientific had already agreed to reduce the jury verdict to approximately $186 million.
0 comments :
Post a Comment